---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-265711"
form_type: "8-K"
ticker: "VRDN"
cik: "0001590750"
company_name: "Viridian Therapeutics, Inc.\\DE"
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:17:33.458056+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Viridian closes $289M equity, $300M royalty financing; BLA submitted for veligrotug in TED

## Summary
- Cash position ~$887.9M as of Oct 31, 2025, up from $490.9M at Sep 30, after equity, royalty, and debt financings.
- BLA for veligrotug (IV) in thyroid eye disease submitted to FDA Oct 2025 with Priority Review request; mid-2026 launch targeted if approved.
- Subcutaneous VRDN-003 topline data accelerated: REVEAL-1 in Q1 2026, REVEAL-2 in Q2 2026; both trials exceeded enrollment targets (132 and 204 patients).
- R&D expenses $86.3M in Q3 2025 (up 25% YoY) driven by Ph3 programs; G&A $24.3M (up 69% YoY) from launch prep.
- VRDN-006 showed IgG reduction proof-of-concept in Ph1; VRDN-008 IND on track for year-end 2025.

## SEC filing metadata
- accession: 0001193125-25-265711
- form_type: 8-K
- ticker: VRDN
- cik: 0001590750
- company_name: Viridian Therapeutics, Inc.\DE
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590750/000119312525265711/0001193125-25-265711-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590750/000119312525265711/d33707d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-265711
- JSON: https://secwatch.observer/filing/0001193125-25-265711.json
- Plain text: https://secwatch.observer/filing/0001193125-25-265711.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.